The complexity of signalling mediated by the glucagon-like peptide-1 receptor

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The glucagon-like peptide-1 receptor (GLP-1R) is a class B GPCR that is a major therapeutic target for the treatment of type 2 diabetes. The receptor is activated by the incretin peptide GLP-1 promoting a broad range of physiological effects including glucose-dependent insulin secretion and biosynthesis, improved insulin sensitivity of peripheral tissues, preservation of β-cell mass and weight loss, all of which are beneficial in the treatment of type 2 diabetes. Despite this, existing knowledge surrounding the underlying signalling mechanisms responsible for the physiological actions downstream of GLP-1R activation is limited. Here, we review the current understanding around GLP-1R-mediated signalling, in particular highlighting recent contributions to the field on biased agonism, the spatial and temporal aspects for the control of signalling and how these concepts may influence future drug development.

Original languageEnglish
Pages (from-to)582-588
Number of pages7
JournalBiochemical Society Transactions
Volume44
Issue number2
DOIs
Publication statusPublished - 15 Apr 2016

Keywords

  • Biased signalling
  • G protein-coupled receptor
  • Glucagon-like peptide-1 receptor
  • Ligand-directed signalling bias

Cite this

@article{6862c669da75465f9dc2e2dfc324f35c,
title = "The complexity of signalling mediated by the glucagon-like peptide-1 receptor",
abstract = "The glucagon-like peptide-1 receptor (GLP-1R) is a class B GPCR that is a major therapeutic target for the treatment of type 2 diabetes. The receptor is activated by the incretin peptide GLP-1 promoting a broad range of physiological effects including glucose-dependent insulin secretion and biosynthesis, improved insulin sensitivity of peripheral tissues, preservation of β-cell mass and weight loss, all of which are beneficial in the treatment of type 2 diabetes. Despite this, existing knowledge surrounding the underlying signalling mechanisms responsible for the physiological actions downstream of GLP-1R activation is limited. Here, we review the current understanding around GLP-1R-mediated signalling, in particular highlighting recent contributions to the field on biased agonism, the spatial and temporal aspects for the control of signalling and how these concepts may influence future drug development.",
keywords = "Biased signalling, G protein-coupled receptor, Glucagon-like peptide-1 receptor, Ligand-directed signalling bias",
author = "Fletcher, {Madeleine M} and Halls, {Michelle L} and Arthur Christopoulos and Sexton, {Patrick M} and Denise Wootten",
year = "2016",
month = "4",
day = "15",
doi = "10.1042/BST20150244",
language = "English",
volume = "44",
pages = "582--588",
journal = "Biochemical Society Transactions",
issn = "0300-5127",
publisher = "Portland Press",
number = "2",

}

TY - JOUR

T1 - The complexity of signalling mediated by the glucagon-like peptide-1 receptor

AU - Fletcher, Madeleine M

AU - Halls, Michelle L

AU - Christopoulos, Arthur

AU - Sexton, Patrick M

AU - Wootten, Denise

PY - 2016/4/15

Y1 - 2016/4/15

N2 - The glucagon-like peptide-1 receptor (GLP-1R) is a class B GPCR that is a major therapeutic target for the treatment of type 2 diabetes. The receptor is activated by the incretin peptide GLP-1 promoting a broad range of physiological effects including glucose-dependent insulin secretion and biosynthesis, improved insulin sensitivity of peripheral tissues, preservation of β-cell mass and weight loss, all of which are beneficial in the treatment of type 2 diabetes. Despite this, existing knowledge surrounding the underlying signalling mechanisms responsible for the physiological actions downstream of GLP-1R activation is limited. Here, we review the current understanding around GLP-1R-mediated signalling, in particular highlighting recent contributions to the field on biased agonism, the spatial and temporal aspects for the control of signalling and how these concepts may influence future drug development.

AB - The glucagon-like peptide-1 receptor (GLP-1R) is a class B GPCR that is a major therapeutic target for the treatment of type 2 diabetes. The receptor is activated by the incretin peptide GLP-1 promoting a broad range of physiological effects including glucose-dependent insulin secretion and biosynthesis, improved insulin sensitivity of peripheral tissues, preservation of β-cell mass and weight loss, all of which are beneficial in the treatment of type 2 diabetes. Despite this, existing knowledge surrounding the underlying signalling mechanisms responsible for the physiological actions downstream of GLP-1R activation is limited. Here, we review the current understanding around GLP-1R-mediated signalling, in particular highlighting recent contributions to the field on biased agonism, the spatial and temporal aspects for the control of signalling and how these concepts may influence future drug development.

KW - Biased signalling

KW - G protein-coupled receptor

KW - Glucagon-like peptide-1 receptor

KW - Ligand-directed signalling bias

UR - http://www.scopus.com/inward/record.url?scp=85009735953&partnerID=8YFLogxK

U2 - 10.1042/BST20150244

DO - 10.1042/BST20150244

M3 - Article

VL - 44

SP - 582

EP - 588

JO - Biochemical Society Transactions

JF - Biochemical Society Transactions

SN - 0300-5127

IS - 2

ER -